Approval
Pfizer's Hympavzi approved in China for hemophilia patients with inhibitors
China extended Hympavzi, Pfizer's weekly subcutaneous anti-TFPI antibody, to routine prophylaxis in people aged 12 and up weighing at least 35 kg with hemophilia A or B and factor inhibitors. In the BASIS phase 3 trial, treated bleeds fell an estimated 93% versus on-demand bypassing agents, and 94.3% of patients cleared all baseline target joints within a year.
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.